News
Resources
Blog
Sites
Recognizing Hepatitis R&D on World Hepatitis Day
By Andrew Powaleny | July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...
Read More
Spending on medicines grew less than one percent in 2017
By Holly Campbell | April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...
Read More
Medicare Monday: Another example of the competitive market at work in Part D
By Nicole Longo | April 17, 2017
Hepatitis C is a devastating viral disease that can result in life-threatening and costly complications. Five years ago, the only available treatment for the disease often resulted in debilitating...
Read More
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
By Nicole Longo | February 13, 2017
The manufacturing and trafficking of counterfeit drugs is not just a U.S. concern but a growing threat globally. Governments around the world are working together to try to prevent these fake...
Read More
Focusing on patients and progress on World Hepatitis Day
By Hannah Mooney Mack | July 28, 2016
World Hepatitis Day is a unique opportunity to take stock of the recent advancements in new treatments and cures to combat versions of hepatitis. Founded by the World Hepatitis Alliance, World...
Read More
New report celebrates a decade of progress in chronic diseases
By Holly Campbell | February 25, 2016
In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases. With about half of all Americans, or 117 million people, living with...
Read More
Local Impact: Hepatitis C and Medicaid spending
By Priscilla VanderVeer | December 22, 2015
There has been a lot of discussion about the cost of new hepatitis C treatments to state Medicaid programs. What has not been addressed, however, is how those costs stack up against older, less...
Read More
Critics proven wrong again on medicine spending
By Holly Campbell | December 9, 2015
Recent comments from pharmacy benefit managers and insurers disprove – once again – the fallacious claims previously made about spending on new innovative medicines. Over the past year, payers...
Read More
Medicare Monday: New hepatitis C treatments in Medicare
By Ashley Flint | November 2, 2015
America’s innovative biopharmaceutical companies are committed to researching and developing treatments that help patients live longer, healthier lives. In recent years new treatments for...
Read More
ICYMI: New cholesterol-lowering medicines will not be “budget busters”
By Holly Campbell | October 8, 2015
In case you missed it, Express Scripts, the nation’s largest pharmacy benefit manager, announced that it will include two new cholesterol-lowering medicines, called PCSK9 inhibitors, on its...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
